Patent ID: 6737060
Filing Date: 2004-05-18
Classification: C07K

Abstract:
A method for in vivo treatment of TAG-72-expressing cancer comprising the steps of (i) intravenously administering a radionuclide-labeled antibody, (ii) thereafter detecting TAG-72-expressing cancer cells using a radionuclide activity probe, and (iii) thereafter removing the detected TAG-72-expressing cancer cells by surgical excision, wherein the antibody is either:A) a humanized antibody having binding specificity to TAG-72 wherein said humanized antibody comprises: 1) at least one NEWM-grafted humanized heavy chain variable region (VH) having the amino acid sequence of any one of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6; and 2) at least one REI-grafted humanized light chain variable region (VL) having the amino acid sequence of SEQ ID NO:9; or B) a humanized antibody fragment having binding specificity to TAG-72, said fragment being a fragment of the humanized antibody of Part A).